KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) Operating Income (2016 - 2025)

Biogen (BIIB) has 17 years of Operating Income data on record, last reported at $1.3 billion in Q4 2025.

  • For Q4 2025, Operating Income fell 6.85% year-over-year to $1.3 billion; the TTM value through Dec 2025 reached $3.5 billion, up 183.61%, while the annual FY2025 figure was $5.7 billion, 91.75% up from the prior year.
  • Operating Income reached $1.3 billion in Q4 2025 per BIIB's latest filing, up from -$117.1 million in the prior quarter.
  • Across five years, Operating Income topped out at $1.4 billion in Q4 2024 and bottomed at -$800.8 million in Q3 2023.
  • Average Operating Income over 5 years is $469.9 million, with a median of $536.4 million recorded in 2021.
  • Peak YoY movement for Operating Income: tumbled 188.82% in 2023, then skyrocketed 1821.32% in 2025.
  • A 5-year view of Operating Income shows it stood at $587.1 million in 2021, then crashed by 94.4% to $32.9 million in 2022, then tumbled by 2534.04% to -$800.8 million in 2023, then soared by 269.97% to $1.4 billion in 2024, then decreased by 6.85% to $1.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Income were $1.3 billion in Q4 2025, -$117.1 million in Q3 2025, and $1.1 billion in Q2 2025.